PTO/S8/25 (07-09)
PTO/S8/25 (0

REJECTION OVER A PENDING "REFERENCE"

in re Application of Matthew L. Tripp, et al.

Application No.: 10/557,293

	OXO	The owner, METAPROTEOMICS, LLC	For
のメび	100	Q.	T) >
	SE	ner	NEW TITE
o a	NOV	الار احدا	
D	ded	AETA	ÖŽ
	be	PRO	
, ;;	Q.X.	1037	0 Q
=	100	MICS	PREVENTION OF GASTRIC TOXICITY
<u> </u>	tern	F	őŽ
2	Buil		Z Z Z Z
7	D D	-	
2	1 3		Z
i S	100		CAL
ב ני ב	sta		CO
֓֞֝֝֟֝֝֟֝֝֝֟֝֝֟֝֓֓֓֟֝֝֟֝֓֓֓֓֟֝֓֓֓֓֓֟֝֓֓֓֓֡֝֟֝֓֓֡֓֡֝֡֓֓֡֓֡֝֡֡֡֡֩֝	tuto		MP
ב ה	y te		osn
j	un.		Š
2	of as	្ម	Ś
ğ	o Y	-1	ÖR
5	ater	ŏ	RE
1	r Q	ת ו	200
3	ante	907	Ž N
j D	ğ	7	7
<u>.</u>	2	nter	
1	e in	est	3
)) 7	stan	ř	AT (
3	gen	ie ii	Ž
0	plica	nsta	Š
	Hion	27 8	1
アング	¥2.	poli	n H
S S	Ĉ,	catic	REA
the expiration date of the full statutory term of any patent granted on panding reference Application Number 11/501 303	except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyo	, of100 percent interest in the instant application hereby disclain	FOR ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS FOR REDUCING INFLAMMATION AND THE TREATMENT OR PREVENTION OF GASTRIC TOXICITY
	0	ere	
	den	o Aq	OR R
	ο σ	Misc.	
ij	ž	ain ain	

on <u>108/09/2006</u> as such term is defined in 35 U.S.C. 154 and 173, and as the term of any patent granted on said reapplication may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application. The hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and an granted on the reference application are commonly owned. This agreement runs with any patent granted on the instant application binding upon the grantee, its successors or assigns. end beyond in reference he owner ny patent on and is

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent granted on said reference application, "as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application," in the event that any such patent granted on the pending reference application: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

Check either box 1 or 2 below, if appropriate

Ŋ	S J D	
	ateme	
2. 🗹 The undersigned is an attorney or agent of record. Reg. No	I hereby declare that all statements made herein of my own knowledge are believed to be true; and further that these statements were made with the made are punishable by fine or imprisonment, or both, under Section 1001 of Title statements may jeopardize the validity of the application or any patent issued thereon.	For submissions on behalf of a business/organization (e.g., corporation, partnershietc.), the undersigned is empowered to act on behalf of the business/organization.
Reg. No.	of my own ments were der Section any patent	ion (e.g., co alf of the bu
59,037	I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilfful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.	1. For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.

ignature

yped or printed name Atabak Royaee

Telephone Number (617) 535-4108

Date 24

2010

Terminal disclaimer fee under コイン CFR 1.20(d) is included

٠,

WARNING: Information on this form may become be included on this form. Provide credit card inf credit card information public. Credit card information should not on and authorization on PTO-2038.

*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).
Form PTO/SB/96 may be used for making this statement. See MPEP § 324.
Form PTO/SB/96 may be used for making this statement. See MPEP § 324.
This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO This collection of information is required by 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.